TRADJENTA (linagliptin) has been
approved by the US Food and Drug
Administration as an add-on
therapy to insulin.
Tradjenta is a prescription
medication used along with diet
and exercise to lower blood sugar
in adults with type 2 diabetes, and
can be used as monotherapy or in
combination with other commonly
prescribed medications for type 2
diabetes, such as metformin,
sulfonylurea, pioglitazone or
insulin.
See www.fda.gov for more.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Aug 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Aug 12
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.